基于PML::RARα基因组结构的急性早幼粒细胞白血病独特白血病发生机制
该研究在短型PML::RARα融合基因的急性早幼粒细胞白血病(APL)亚型中,发现白血病干细胞(LSC)富集于CD34+CD38-组分并表达TIM-3,且能在异种移植模型中高效重建人APL并进行连续移植,表明短型APL存在层级组织化的自我更新APL-LSC。
要点
- 短型APL的LSC富集于CD34+CD38-组分并表达TIM-3。
- CD34+CD38-TIM-3+短型APL细胞在异种移植模型中高效重建人APL。
- CD34+CD38-TIM-3+短型APL细胞可在连续移植后重建白血病细胞。
核心结论
- 短型APL由自我更新的APL-LSC层级组织化,LSC存在于部分APL亚型中。
- 建立的高效患者来源异种移植模型可能有助于进一步理解APL白血病发生并设计个体化治疗以根除APL LSC。
研究设计与样本
- 研究比较短型与其他类型APL的基因表达特征,并用异种移植模型评估CD34+CD38-TIM-3+短型APL细胞的重建能力。
主要发现
- 短型APL细胞的CD34+CD38-组分富集LSC并表达TIM-3,其基因表达特征与其他类型APL不同,包含LSC相关基因。
- CD34+CD38-TIM-3+短型APL细胞在异种移植模型中以高穿透率高效重建人APL,而CD34-分化APL细胞未能重建。
- CD34+CD38-TIM-3+短型APL细胞在连续移植后重建白血病细胞。
关键数值与推荐
- APL占所有AML病例的10%,由PML::RARα融合基因驱动。
- 短型APL由PML基因不同断裂点定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukemic stem cells (LSCs) of acute myeloid leukemia (AML) can be enriched in the CD34+CD38- fraction and reconstitute human AML in vivo. However, in acute promyelocytic leukemia (APL), which constitutes 10% of all AML cases and is driven by promyelocytic leukemia-retinoic acid receptor alpha (PML::RARα) fusion genes, the presence of LSCs has long been unidentified because of the difficulty in efficient reconstitution of human APL in vivo. Herein, we show that LSCs of the short-type isoform APL, a subtype of APL defined by different breakpoints of the PML gene, concentrate in the CD34+CD38- fraction and express T cell immunoglobulin mucin-3 (TIM-3). Short-type APL cells exhibited distinct gene expression signatures, including LSC-related genes, compared to the other types of APL. Moreover, CD34+CD38-TIM-3+ short-type APL cells efficiently reconstituted human APL in xenograft models with high penetration, whereas CD34- differentiated APL cells did not. Furthermore, CD34+CD38-TIM-3+ short-type APL cells reconstituted leukemia cells after serial transplantation. Thus, short-type APL was hierarchically organized by self-renewing APL-LSCs. The identification of LSCs in a subset of APL and establishment of an efficient patient-derived xenograft model may contribute to further understanding the APL leukemogenesis and devise individual treatments for the eradication of APL LSCs.
引用
- Minami M, Sakoda T, Kawano G, et al. Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARα. Leukemia. 2025. PMID: 39979604. doi:10.1038/s41375-025-02530-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。